GGrantIndex
← Leaderboards

Ping Mu

Sloan-Kettering Inst Can Research

Google Scholar ↗PubMed ↗ORCID ↗
$4,365,544
Attributed
$4,365,544
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY2017–25
$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,365,544 · 5

By mechanism

R37$2,269,749 · 1
R01$1,230,467 · 2
R00$719,139 · 1
K99$146,189 · 1

Top collaborators

No co-investigators on record.

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Molecular”

Research focus

MolecularTargeted TreatmentMalignant Neoplasm Of ProstateResistanceCellsMediatingInsightIn VivoTumorResistance MechanismTherapeutic TargetDna Sequence AlterationScreeningNeoplastic CellTumor Suppressor GenesDeaminaseGenesPathway InteractionsAdvanced Prostate CancerLibrariesOrganoidsPatient-Focused OutcomesKnock-DownCancer Patient

Grant awards (18)

Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor Degradation$416,619
R01 · FY2025 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$410,480
R37 · FY2025 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$467,016
R37 · FY2024 · CA · contact PI
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor Degradation$399,714
R01 · FY2024 · CA · contact PI
Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate Cancer$397,668
R01 · FY2024 · CA · contact PI
Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate Cancer$8,266
R01 · FY2024 · CA · contact PI
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor Degradation$8,200
R01 · FY2024 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$3,549
R37 · FY2024 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$1
R37 · FY2024 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$400,194
R37 · FY2023 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$85,232
R37 · FY2023 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$408,360
R37 · FY2022 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$86,972
R37 · FY2022 · CA · contact PI
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance$407,945
R37 · FY2021 · CA · contact PI
Overcome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancer$249,000
R00 · FY2020 · CA · contact PI
Overcome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancer$221,139
R00 · FY2019 · CA · contact PI
Overcome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancer$249,000
R00 · FY2018 · CA · contact PI
Overcome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancer$146,189
K99 · FY2017 · CA · contact PI